Erica Park

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Colin D. Weekes, A. Craig Lockhart, Patricia LoRusso et al. · The Oncologist · 2020 · 52 citations · Full text

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick et al. · Clinical Cancer Research · 2019 · 42 citations · Full text

Management of complicated airway foreign body aspiration using extracorporeal membrane oxygenation (ECMO)

Albert H. Park, David E. Tunkel, Erica Park et al. · International Journal of Pediatric Otorhinolaryngology · 2014 · 31 citations

Ventilation, Artificial Respiration, Oxygen Therapy +6

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with <i>BRAF</i>^V600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

Brigitte Dréno, Paolo A. Ascierto, Grant A. McArthur et al. · Journal of Clinical Oncology · 2018 · 27 citations

Cancer Management, Pathology, Overall Survival +17

Abstract CT107: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

Colin D. Weekes, Albert Lockhard, Patricia LoRusso et al. · Cancer Research · 2017 · 11 citations

Phase Ib Study, Tumor Biology, Mek Inhibitor Cobimetinib +15